Plain-English translation of NCT07844967 on ClinicalTrials.gov ↗ ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are studying how , an experimental new medication, is processed by the body differently in people who have liver disease compared to people with healthy livers. This is an early-stage study (Phase 1) designed to understand whether liver problems change how much of the medication enters the bloodstream and how quickly the body clears it. The information will help doctors decide if the medication is safe and effective for people with liver disease.
The liver is responsible for breaking down most medications in the body. When someone has liver disease, medications may not be processed normally, which could lead to unsafe medication levels in the blood. This trial exists to understand whether people with liver disease need different doses or precautions when taking this new medication.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be assigned to one of four groups: people with moderate liver disease, people with mild liver disease, or healthy controls matched by age, gender, and body weight. You will come to a research clinic the day before the study, fast overnight, and on the next morning receive a single 20 mg oral dose of the medication with water. You'll stay at the clinic for several hours while researchers draw blood samples at scheduled times to measure how your body processes the medication. The study is designed to last just a few days, though follow-up visits may be scheduled to check on your health.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
China